JP2023507795A5 - - Google Patents
Info
- Publication number
- JP2023507795A5 JP2023507795A5 JP2022538201A JP2022538201A JP2023507795A5 JP 2023507795 A5 JP2023507795 A5 JP 2023507795A5 JP 2022538201 A JP2022538201 A JP 2022538201A JP 2022538201 A JP2022538201 A JP 2022538201A JP 2023507795 A5 JP2023507795 A5 JP 2023507795A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- approximately
- variable region
- chain variable
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025207453A JP2026048712A (ja) | 2019-12-20 | 2025-11-28 | 第ＸＩ／ＸＩａ因子抗体の医薬製剤および投薬レジメン |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962951887P | 2019-12-20 | 2019-12-20 | |
| US62/951,887 | 2019-12-20 | ||
| PCT/US2020/066151 WO2021127525A1 (en) | 2019-12-20 | 2020-12-18 | Pharmaceutical formulations and dosage regimens for factor xi/xia antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025207453A Division JP2026048712A (ja) | 2019-12-20 | 2025-11-28 | 第ＸＩ／ＸＩａ因子抗体の医薬製剤および投薬レジメン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023507795A JP2023507795A (ja) | 2023-02-27 |
| JP2023507795A5 true JP2023507795A5 (https=) | 2023-12-15 |
Family
ID=76478578
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022538201A Pending JP2023507795A (ja) | 2019-12-20 | 2020-12-18 | 第ＸＩ／ＸＩａ因子抗体の医薬製剤および投薬レジメン |
| JP2025207453A Pending JP2026048712A (ja) | 2019-12-20 | 2025-11-28 | 第ＸＩ／ＸＩａ因子抗体の医薬製剤および投薬レジメン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025207453A Pending JP2026048712A (ja) | 2019-12-20 | 2025-11-28 | 第ＸＩ／ＸＩａ因子抗体の医薬製剤および投薬レジメン |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230071973A1 (https=) |
| EP (1) | EP4076511A4 (https=) |
| JP (2) | JP2023507795A (https=) |
| KR (1) | KR20220119090A (https=) |
| CN (1) | CN115003325A (https=) |
| BR (1) | BR112022012064A2 (https=) |
| CA (1) | CA3161118A1 (https=) |
| IL (1) | IL293367A (https=) |
| WO (1) | WO2021127525A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024540435A (ja) * | 2021-11-18 | 2024-10-31 | アントス セラピューティクス， インコーポレイテッド | 第ＸＩ／ＸＩａ因子抗体の投薬レジメン |
| TW202333789A (zh) * | 2022-01-05 | 2023-09-01 | 大陸商上海邁晉生物醫藥科技有限公司 | 一種包含抗ＦＸＩ／ＦＸＩａ抗體的醫藥組成物及其用途 |
| DE102022116219A1 (de) * | 2022-06-29 | 2024-01-04 | St. Jude Medical, Cardiology Division, Inc. | Kandidatenscreening für eine Zieltherapie |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8476239B2 (en) * | 2005-12-20 | 2013-07-02 | Bristol-Myers Squibb Company | Stable protein formulations |
| US20100129379A1 (en) * | 2006-09-25 | 2010-05-27 | John Carpenter | Stabilized antibody formulations and uses thereof |
| CN106038481A (zh) * | 2007-06-28 | 2016-10-26 | 锡德克斯药物公司 | 皮质类固醇水溶液的鼻部和眼部给药 |
| LT2953969T (lt) * | 2013-02-08 | 2019-12-10 | Novartis Ag | Anti-il-17a antikūnai ir jų panaudojimas autoimuninių ir uždegiminių ligų gydymui |
| UY36751A (es) * | 2015-06-26 | 2017-01-31 | Novartis Ag | Anticuerpos de factor xi y métodos de uso |
| MX2018002166A (es) * | 2015-08-20 | 2018-09-12 | Abbvie Stemcentrx Llc | Conjugados anticuerpo anti-dll3-farmaco y metodos de uso. |
| IL267519B2 (en) * | 2016-12-23 | 2025-04-01 | Novartis Ag | Factor XI/XIA for use in the prevention, treatment, management, or reduction of the risk of stroke or thromboembolism in a patient with end-stage renal disease |
| AU2017383232B2 (en) * | 2016-12-23 | 2024-09-12 | Novartis Ag | Factor XI antibodies and methods of use |
| US20190367636A1 (en) * | 2017-01-19 | 2019-12-05 | Bayer Pharma Aktiengesellschaft | Novel stable formulation for fxia antibodies |
| JOP20190260A1 (ar) * | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| EP3713965A1 (en) * | 2017-11-22 | 2020-09-30 | Novartis AG | Reversal binding agents for anti-factor xi/xia antibodies and uses thereof |
| JP2024540435A (ja) * | 2021-11-18 | 2024-10-31 | アントス セラピューティクス， インコーポレイテッド | 第ＸＩ／ＸＩａ因子抗体の投薬レジメン |
-
2020
- 2020-12-18 US US17/785,660 patent/US20230071973A1/en active Pending
- 2020-12-18 EP EP20903182.2A patent/EP4076511A4/en active Pending
- 2020-12-18 WO PCT/US2020/066151 patent/WO2021127525A1/en not_active Ceased
- 2020-12-18 CA CA3161118A patent/CA3161118A1/en active Pending
- 2020-12-18 JP JP2022538201A patent/JP2023507795A/ja active Pending
- 2020-12-18 IL IL293367A patent/IL293367A/en unknown
- 2020-12-18 BR BR112022012064A patent/BR112022012064A2/pt unknown
- 2020-12-18 CN CN202080093971.9A patent/CN115003325A/zh active Pending
- 2020-12-18 KR KR1020227024670A patent/KR20220119090A/ko active Pending
-
2025
- 2025-11-28 JP JP2025207453A patent/JP2026048712A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250074985A1 (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| US9220776B2 (en) | Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments | |
| JP2021046431A (ja) | 血管性眼疾患を処置するための方法および製剤 | |
| KR20200034739A (ko) | 고농도 항-c5 항체 제형 | |
| BR112021008778A2 (pt) | Métodos de tratamento da oftalmopatia de graves usando anticorpos anti-fcrn | |
| KR102296017B1 (ko) | 혈관 질환 및 이에 따른 합병증 치료 | |
| TWI894144B (zh) | 藉由投予il-33拮抗劑治療或預防哮喘之方法 | |
| TW201501724A (zh) | 低濃度抗體調配物 | |
| WO2020259605A1 (zh) | 包含抗cd47/pd-l1双特异性抗体的制剂及其制备方法和用途 | |
| JP2023507795A5 (https=) | ||
| TW202045537A (zh) | 化膿性汗腺炎的治療 | |
| CN113194821A (zh) | 逆转替卡格雷活性的方法 | |
| JP2026048712A (ja) | 第ＸＩ／ＸＩａ因子抗体の医薬製剤および投薬レジメン | |
| TW202128133A (zh) | 重組全人源抗ｔｉｇｉｔ單株抗體製劑及其製備方法和用途 | |
| KR20250079929A (ko) | 항-FcRN 항체를 이용한 그레이브스병의 치료 방법 | |
| WO2023174408A1 (zh) | 抗tim-3抗体与抗pd-l1抗体的药物组合 | |
| RU2745814C1 (ru) | Водная фармацевтическая композиция левилимаба и ее применение | |
| CN116172947A (zh) | 一种含特异性结合vegf和ang2的双特异性抗体的药物组合物 | |
| TW202206457A (zh) | 用於治療呼吸疾病之泛elr+ cxc趨化因子抗體 | |
| CN116688115B (zh) | 一种PD-L1/TGF-β双功能融合蛋白制剂及其用途 | |
| BR112021004900A2 (pt) | anticorpos de quimiocina pan-elr+ cxc para o tratamento de hidradenitis suppurativa | |
| JP2019505516A (ja) | インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法 | |
| HK40102408B (zh) | 含抗lag-3抗体的药物组合物及其用途 | |
| WO2025130748A1 (zh) | 一种抗凝血因子XI/XIa抗体制剂 | |
| CN115916820A (zh) | 用il6拮抗剂治疗包括covid-19肺炎在内的肺炎的方法 |